Indian stocks: Visit www.stage2stocks.com →

AIM ImmunoTech Inc.

Stage 4 · Declining · week 62

As of Oct 22, 2026, AIM ImmunoTech is in Stage 4, the downtrend phase, now in week 62 (since Jul 31, 2025). It closed at $0.16, 94.0% below its 52-week high and below its 200-day average, which is falling.

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. More about the company

$0.16
-6.92% today
$6.4M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is AIM early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 55w
S4 64w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 6w → S3 5w → S4 8w → S1 4w → S4 11w → S1 9w → S4 55w → S1 4w → S4 64w current
Total tracked: 166 weeks across 9 stage runs.

AIM among Biotechnology516th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…516AIMStage 4 · wk 626−23.8%
vs 52W High
-94.0%
$0.16 lo$2.68 hi
94.0% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 62
1w13w26w
Week 62, extended decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-69.2%
200 DMA: $0.52 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.07x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-23.8%
3M
-36.0%
6M
-69.2%
YTD
-86.1%
1Y
-93.7%
Scan Membership
Breakout Watch
Latest: 2023-07-06
4 appearances in last 60 days. First seen: 2020-03-27.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 62 · Vol 0.07x
2026-10-21S4
Wk 62 · Vol 0.04x
2026-10-20S4
Wk 62 · Vol 0.05x
2026-10-19S4
Wk 62 · Vol 0.09x
2026-10-16S4
Wk 62 · Vol 0.06x
2026-10-15S4
Wk 61 · Vol 0.18x
2026-10-14S4
Wk 61 · Vol 0.10x
2026-10-13S4
Wk 61 · Vol 0.10x
2026-10-12S4
Wk 61 · Vol 0.08x
2026-10-09S4
Wk 61 · Vol 0.07x
2026-10-08S4
Wk 60 · Vol 0.08x
2026-10-07S4
Wk 60 · Vol 0.09x
Moving averages & range
50 DMA
$0.21
200 DMA
$0.52
52W High
$2.68
52W Low
$0.16
5D Low
$0.16
Resistance levels (recent highs)
20d High
$0.19
60d High
$0.29
120d High
$0.90
250d High
$2.68
Next resistance
+18.8%
to 20d High
ROE
-2382.3%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.6

AIM ImmunoTech: quick answers

What stage is AIM ImmunoTech in?

As of Oct 22, 2026, AIM ImmunoTech (AIM) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 31, 2025 and is in week 62. What the four stages mean

Is AIM ImmunoTech in an uptrend?

No. AIM ImmunoTech is in a Stage 4 downtrend. It trades 69.2% below its 200-day average, which is falling.

How far is AIM ImmunoTech from its 52-week high?

AIM ImmunoTech closed at $0.16 on Oct 22, 2026, 94.0% below its 52-week high of $2.68. Its 52-week low is $0.16.

How has AIM ImmunoTech performed over the past year?

As of Oct 22, 2026, AIM ImmunoTech is down 93.7% over the past year and down 86.1% so far in 2026.

Which sector and industry is AIM ImmunoTech in?

AIM ImmunoTech is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.